Enhancement of cisplatin cytotoxicity by terbium in cisplatin-resistant MDA/CH human breast cancer cells

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 3, 1999, Pages 249-252

  Fuller, Teresa L ^a   Canada, Robert G ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Cisplatin; Cytotoxicity; MDA MB 231; Resistance; Terbium

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; TERBIUM;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL SURVIVAL; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BREAST NEOPLASMS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; TERBIUM; TUMOR CELLS, CULTURED;

EID: 0032770421     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050974     Document Type: Article

References (21)

1. 1. Berg J, Hutter R (1995) Breast cancer. Cancer 75: 257
2. 2. Canada R (1986) Terbium fluorescence studies of cisplatin binding to GH3/B6 pituitary tumor cells. Biochim Biophys Acta 887: 29
3. 3. Canada R, Paltoo D (1998) Binding of terbium and cisplatin to C13* human ovarian cancer cells using time-resolved terbium luminescence. Biochim Biophys Acta 1448: 85
4. 4. Canada R, Andrews P, Mack K, Haider A (1995) The effects of terbium on the accumulation of cisplatin in human ovarian cancer cells. Biochim Biophys Acta 1267: 25
5. 5. Chao C (1996) Molecular basis of cis-diamminedichloroplatinum(II) resistance: a review. J Formos Med Assoc 95: 893
6. 6. Chou T, Hayball M (1996) CalcuSyn: Windows software for dose effect analysis. Biosoft, Cambridge, UK
7. 7. Evans C (1990) Toxicology and pharmacology of the lanthanides. In: Biochemistry of the lanthanides. Plenum Press, New York
8. 3+ in human breast cancer cells via the terbium-cisplatin binding protein. Biophys J 74: A88
9. 9. Jekunen A, Shalinsky D, Hom D, Albright K, Heath D, Howell S (1993) Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane by digitonin in vitro. Biochem Pharmacol 45: 2079
10. 10. Kelsey J, Bernstein L (1996) Epidemiology and prevention of breast cancer. Annu Rev Public Health 17: 47
11. 11. Mack K, Canada R, Andrews P (1997) The effects of terbium on the cellular accumulation of cisplatin in MDA-MB-231 human breast tumor cells. Cancer Chemother Pharmacol 39: 217
12. 12. McGuire W, Hoskins W, Brady M, Kucera P, Partridge E, Look K, Clarke-Pearson D, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1
13. 13. Moormeier J (1996) Breast cancer in black women. Ann Intern Med 124: 897
14. 14. Onoda J, Nelson K, Taylor J, Honn K (1989) In vivo characterization of combination antitumor chemotherapy with calcium blockers and cis-diamminedichloroplatinum(II). Cancer Res 49: 2844
15. 15. Paltoo D, Canada R (1998) Effects of terbium on the cytotoxicity of cisplatin in FaDu human head and neck squamous cell carcinoma. Cancer Biochem Biophys 16: 213
16. 16. Perez R, Hamilton T, Ozols R, Young R (1993) Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 71: 1571
17. 17. Sledge G (1992) Cisplatin and platinum analogues in breast cancer. Semin Oncol 19: 78
18. 18. Timmer-Bosscha H, Mulder N, De Vries E (1992) Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer 66: 227
19. 19. Tolcher A (1996) Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Semin Oncol 23: 37
20. 20. Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuch-Jacquotte A, Blum R, Speyer J (1996) Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol 14: 1993
21. 21. Zoli W, Flamigni A, Frassineti G, Bajorko P, De Paola F, Milandri C, Amadori D, Gasperi-Campani A (1995) In vitro activity of Taxol and Taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers. Breast Cancer Res Treat 34: 63